Related Experiment Videos
PTEN/MMAC1/TEP1 involvement in primary prostate cancers
Oncogene
|July 22, 1998
Summary
The PTEN gene, a tumor suppressor, was investigated for its role in prostate cancer. A somatic mutation was found in one tumor, suggesting PTEN mutations may contribute to prostate tumorigenesis.
Area of Science:
- Oncology
- Genetics
- Molecular Biology
Background:
- The PTEN gene (Phosphatase and tensin homolog) is a critical tumor suppressor.
- PTEN mutations are implicated in various cancers, including prostate cancer.
- Loss of heterozygosity (LOH) at chromosome 10q22-24 is frequently observed in prostate tumors.
Purpose of the Study:
- To investigate the role of the PTEN gene in prostate tumorigenesis.
- To analyze primary prostate tumors for LOH in the 10q22-23 region.
- To identify somatic PTEN mutations in tumors with hemizygous loss.
Main Methods:
- Analysis of 22 primary prostate tumors for LOH at 10q22-23.
- Examination of six tumors with allele loss for somatic PTEN mutations.
- Sequencing of the PTEN coding region.
Main Results:
- LOH was detected in 12 out of 22 (55%) primary prostate tumors.
- Six tumors showed allele loss within the 10q22-23 region, encompassing the PTEN gene.
- One tumor (17%) exhibited a 1 bp deletion in exon 7 of PTEN, indicating a somatic mutation.
Conclusions:
- Somatic mutations in the PTEN gene can occur in primary prostate tumors.
- These findings suggest PTEN alterations contribute to prostate cancer development.
- Further research is warranted to elucidate the full impact of PTEN in prostate tumorigenesis.